- Home
- BCO vs ZLAB Comparison
BCO vs ZLAB Comparison
Compare BCO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCO
- ZLAB
- Stock Information
- Founded
- BCO 1859
- ZLAB 2013
- Country
- BCO United States
- ZLAB China
- Employees
- BCO N/A
- ZLAB N/A
- Industry
- BCO Oil Refining/Marketing
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- BCO Consumer Discretionary
- ZLAB Health Care
- Exchange
- BCO Nasdaq
- ZLAB Nasdaq
- Market Cap
- BCO 3.7B
- ZLAB 3.6B
- IPO Year
- BCO N/A
- ZLAB 2017
- Fundamental
- Price
- BCO $94.46
- ZLAB $36.40
- Analyst Decision
- BCO Strong Buy
- ZLAB Buy
- Analyst Count
- BCO 1
- ZLAB 5
- Target Price
- BCO $138.00
- ZLAB $54.28
- AVG Volume (30 Days)
- BCO 354.8K
- ZLAB 886.6K
- Earning Date
- BCO 08-06-2025
- ZLAB 08-05-2025
- Dividend Yield
- BCO 1.08%
- ZLAB N/A
- EPS Growth
- BCO 41.25
- ZLAB N/A
- EPS
- BCO 3.72
- ZLAB N/A
- Revenue
- BCO $5,022,500,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- BCO $3.91
- ZLAB $44.07
- Revenue Next Year
- BCO $4.45
- ZLAB $49.13
- P/E Ratio
- BCO $25.42
- ZLAB N/A
- Revenue Growth
- BCO 1.97
- ZLAB 43.72
- 52 Week Low
- BCO $80.10
- ZLAB $16.01
- 52 Week High
- BCO $115.91
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- BCO 73.67
- ZLAB 52.67
- Support Level
- BCO $88.22
- ZLAB $34.79
- Resistance Level
- BCO $90.24
- ZLAB $36.73
- Average True Range (ATR)
- BCO 2.10
- ZLAB 1.23
- MACD
- BCO 0.96
- ZLAB -0.46
- Stochastic Oscillator
- BCO 97.54
- ZLAB 25.91
About BCO Brinks Company (The)
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.